P23 Asthma exacerbation rates as a function of biomarker levels 4 weeks after initiation of tezepelumab treatment: an analysis of the NAVIGATOR study

• DOI: 10.1136/thorax-2024-btsabstracts.184
• Publication Date: 2024-11-04T09:40:54Z
• Authors: E Israel; GL Chupp; NL Lugogo; J-P Llanos; NL Martin; N Martin; CS Ambrose; DJ Jackson
• Keywords: Asthma Exacerbations

<h3>Introduction and Objectives</h3> Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in asthma pathogenesis. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized exacerbation rate (AAER) patients with severe, uncontrolled versus placebo, across baseline inflammatory biomarker levels. This <i>post hoc</i> analysis of evaluated AAER receiving or placebo by blood eosinophil counts (BECs) fractional exhaled nitric oxide (FeNO) levels at week 4 treatment. <h3>Methods</h3> was multicenter, randomized, double-blind, placebo-controlled study. Patients (12–80 years old) were randomized to 210 mg subcutaneously every weeks for up 52 weeks. The relationships between BECs FeNO unadjusted over visualized using locally weighted regression smoothing scatterplots treatment group (DIRECT method parameter equal 1). <h3>Results</h3> Of 1059 (tezepelumab, n=528; n=531) overall full set, 1020 n=509; n=511) 985 n=492; n=493) included BEC level analyses, respectively. group, there trends higher AAERs increasing (<b>figure 1</b>). lower than consistent continuum <h3>Conclusions</h3> recipients, post-treatment had no prognostic value rates, contrast expected observed among recipients. These data suggest elevated after initiation cannot be used as clinical predictors non-response.